MarginsXMarginsX
Home › Markets › Health Care › INCR

Intercure Ltd. (INCR)

INCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.63
-4.22% on the day
Market cap
$54.5M
Micro cap
Revenue · 2025
$84.2M
+13.1% on 2024
Net income · 2025
-$11.1M
-13.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1857030/000149315226020743/0001493152-26-020743-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from ILS at 3.2107 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerINCR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001857030
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$84.2M
Net income-$11.1M
Operating income-$8.5M
Net margin-13.2%
Operating margin-10.1%
Revenue growth+13.1%
Cash$14.5M
Total assets$215.1M
P/E (computed)Net income was not positive
P/S (computed)0.6×

Reported in ILS; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
46.5M ILS cash at December 31, 2025
Share count, 1 year
+15.9%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed April 30, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-30
Cash and burn46.5M ILS cash; operating cash flow 4.2M ILS a quarter.Report 2025-12-31
Shares outstanding10,936,267 (2025-12-31); 47,162,713 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-5 on 2026-08-24Source 2026-08-24
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorSomekh Chaikin, Tel Aviv, IsraelPCAOB Form AP 2026-05-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
270.2M ILS-35.7M ILS16.8M ILS46.5M ILS148.0M ILS270.2M ILS20-F 2026-04-30
FY 2024
2024-12-31
238.8M ILS-67.8M ILS-66.9M ILS78.3M ILS183.0M ILS238.8M ILS20-F 2025-05-01
FY 2023
2023-12-31
355.6M ILS-62.0M ILS-53.6M ILS101.1M ILS170.0M ILS355.6M ILS20-F 2025-05-01
FY 2022
2022-12-31
388.7M ILS44.8M ILS51.3M ILS232.6M ILS227.0M ILS388.7M ILS20-F 2025-05-01
FY 2021
2021-12-31
219.7M ILS4.7M ILS30.1M ILS196.2M ILS82.4M ILS219.7M ILS20-F 2024-05-01
FY 2020
2020-12-31
65.0M ILS-37.2M ILS7.9M ILS37.9M ILS745K ILS65.0M ILS20-F 2023-05-01
FY 2019
2019-12-31
8.9M ILS-5.9M ILS-11.6M ILS27.3M ILSNo debt tags8.9M ILS20-F 2022-04-28

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in ILS.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2022-06-23
Latest annual report20-F2026-04-30
Latest quarterly / interim6-K2026-09-08

Source: SEC EDGAR submissions feed, 119 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.2%
1 month-24.7%
3 months-18.1%
Year to date-16.7%
1 year-44.7%
From 52-week high-47.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M
CINGCingulate Inc.$3.75-12.79%$54.5M
XLOXilio Therapeutics Inc.$7.70-3.08%$54.4M
HRTXHeron Therapeutics Inc.$0.2843-8.44%$54.1M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
CLNNClene Inc.$3.66-6.63%$52.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier